Holen Sie sich die Stockscreener-App
0.9502
1.38%
-0.0133
Vorhandelsmarkt:
.94
-0.0102
-1.07%
Schlusskurs vom Vortag:
$0.9635
Offen:
$0.9436
24-Stunden-Volumen:
42,417
Relative Volume:
0.18
Marktkapitalisierung:
$4.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.13M
KGV:
-0.1984
EPS:
-4.79
Netto-Cashflow:
$-16.95M
1W Leistung:
-4.06%
1M Leistung:
+4.09%
6M Leistung:
+65.63%
1J Leistung:
+502.54%
1-Tages-Spanne:
$0.9436
$0.9999
1-Wochen-Bereich:
$0.9115
$1.04
52-Wochen-Spanne:
$0.09
$4.49
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Firmenname
Matinas Biopharma Holdings Inc
Sektor
Branche
Telefon
908-443-1860
Adresse
1545 Route 206 South, Suite 302, Bedminster, NJ
Vergleichen Sie MTNB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.9502 | 5.04M | 0 | -21.13M | -16.95M | -4.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-08-26 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2020-01-09 | Eingeleitet | Aegis Capital | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Matinas Biopharma Holdings Inc Aktie (MTNB) Neueste Nachrichten
Is Matinas BioPharma Holdings Inc. a good long term investmentExplosive capital gains - Autocar Professional
What analysts say about HASI stockFree Investment Timing Strategies - jammulinksnews.com
How Matinas BioPharma Holdings Inc. stock performs during market volatilitySmart Return Focused Trading - Newser
Matinas BioPharma Holdings Inc. Stock Analysis and ForecastBreakout profit opportunities - jammulinksnews.com
What drives Matinas BioPharma Holdings Inc. stock priceFree Stock Market Mentorship - jammulinksnews.com
What analysts say about Matinas BioPharma Holdings Inc. stockExceptional portfolio growth - Autocar Professional
Is Renovaro Inc. a good long term investmentSuperior capital gains - jammulinksnews.com
What makes Matinas BioPharma Holdings Inc. stock price move sharplyShort Squeeze Radar - beatles.ru
What analysts say about WRAP stockOutstanding capital returns - jammulinksnews.com
Why Matinas BioPharma Holdings Inc. stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
Why Hayward Holdings Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Aspergillosis Pipeline 2025: FDA Updates, Therapy - openPR.com
Diversification Wins: Global ETFs Shine in First Half of 2025 - The Globe and Mail
MTNB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum - Kalkine Media
Matinas Biopharma (NYSE:MTNB) Trading 5.7% Higher – Here’s Why - Defense World
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Matinas BioPharma amends bylaws, updates on officer agreements By Investing.com - Investing.com Canada
Matinas BioPharma Amends Bylaws and Sets Annual Meeting - TipRanks
Matinas BioPharma amends bylaws, updates on officer agreements - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Matinas Biopharma (NYSE:MTNB) Shares Down 2.6% – Here’s What Happened - Defense World
MTNB stock touches 52-week low at $0.48 amid sharp annual decline - Investing.com Australia
MTNB stock touches 52-week low at $0.48 amid sharp annual decline By Investing.com - Investing.com South Africa
Matinas BioPharma secures shareholder nods on key proposals By Investing.com - Investing.com Australia
Matinas BioPharma secures shareholder nods on key proposals - Investing.com
Finanzdaten der Matinas Biopharma Holdings Inc-Aktie (MTNB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):